Whole Genome Sequencing for Blood Group Genotyping and Definition as Exemplified on U- and St(a)+. (Blood Genome)

Applicability of Whole Genome Sequencing for Human Blood Group Genotyping and Genetic Definition of New Alleles as Exemplified on References and the Two MNSs-variants: U- and Stones(a)+

No health condition(s) are studied. Genetic background of blood groups is studied. U- and Stones(a)+ ("Caucasian type") are used as proof-of-principle samples. Disease associations of all blood group genes investigated are very rare, e.g. < 1 among 1'000 Swiss individuals (see table 1), and are not to be expected in the course of this study.

Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent.

Study Overview

• Status: Unknown
• Conditions: Genetic Blood Group (bg) Polymorphism in U Negativity and St(a) of MNSs
• Intervention / Treatment: Other: Whole Genome Sequencing (WGS)

Detailed Description

All 34 human blood group systems have at least two antithetical antigens and are of potential relevance during pregnancy and transfusion. Fortunately for every day routine practice, immunizations to foreign antigens are rare. Still, incompatibilities may occur in all blood group systems and will then require typing for the respective blood group antigens.

Blood genotyping evolved as the method of choice, in cases when typing reagents are commercially unavailable, or blood is inaccessible (foetus). In databases, most entries of blood group genes lack representative polymorphism (e.g. number of alleles). Moreover, many blood group antigens are insufficiently described in their intronic and inter-genetic sequences. This is true for results of unequal crossing-overs, gene-conversions and large insertions/deletions between highly homologous genes, especially within the blood group systems of Rhesus, e.g. RhD/RhCE and MN/Ss, respectively. Only Whole Genome Sequencing (WGS) allows for resolution of both problems: it delivers the whole blood group genome of an individual, and simultaneously recognizes new blood group alleles, or haplotypes. This request for ethical approval wants to test this assumption.

The antigenic determinants U- and Stones(a)+ of the blood group system MNSs still lack full genetic description and will serve as challenging examples for the description of new alleles (haplotypes) caused by large ins/del mutations of the two highly homologous genes GYPA and B. Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent. Additional reference samples (n max=4), and samples with suspected Stones(a)+ (n max=4) will be recruited from Zurich blood donors with informed consent, only.

• Study Type: Observational
• Enrollment (Anticipated): 8

Contacts and Locations

Study Locations

• Switzerland
  • Zürich
    • Schlieren, Zürich, Switzerland, 8952
      • Recruiting
      • Blutpende Zürich, Dienstleistungszentrum
      • Contact: Christoph Gassner, PhD; Phone Number: +41 58 272 5195; Email: c.gassner@zhbsd.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 66 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent. Additional reference samples (n max=4), and samples with suspected Stones(a)+ (n max=4) will be recruited from Zurich blood donors with informed consent, only

Description

Inclusion Criteria:

• Existing biomaterial (gDNA), or
• Existing health related data for blood group U- (n max=2) and eligible for (venous) blood sampling of 20 mL, or
• Existing blood group pheno- and genotyping data indicating St(a)+ and eligible for (venous) blood sampling of 20 mL (n max=2), or
• Adequate blood group profile serving as reference (n max =4 & n max =4'000) and eligible for (venous) blood sampling of 20 mL.

Exclusion Criteria:

• Ineligible for venous blood sampling of approx. 20 mL.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
people negative in bg MNSs antigen U; Blood group (bg) system MNSs. Individuals with phenotype "U-". Homo- and heterozygous individuals may be considered.	Other: Whole Genome Sequencing (WGS); There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
people positive in bg MNSs antigen St(a); Blood group (bg) system MNSs. Individuals with phenotype "St(a)+". Homo- and heterozygous individuals may be considered.	Other: Whole Genome Sequencing (WGS); There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Whole Genome Sequencing for the definition of genetic background for blood group antigens U-, St(a)+	During a 2 year time-period, whole genome sequencing data generation and analysis will be used for the analysis and description of the genetic background for the blood group antigens U negativity, and for St(a).	2 year period

Collaborators and Investigators

• Sponsor: Blood Donation Service Zurich, SRC
• Investigators: Principal Investigator: Christoph Gassner, PhD, Blutspende Zürich, Dienstleistungszentrum

Study record dates

Study Major Dates

• Study Start: July 1, 2015
• Primary Completion (Anticipated): June 1, 2016
• Study Completion (Anticipated): June 1, 2018

Study Registration Dates

• First Submitted: August 10, 2015
• First Submitted That Met QC Criteria: August 24, 2015
• First Posted (Estimate): August 27, 2015

Study Record Updates

• Last Update Posted (Estimate): August 27, 2015
• Last Update Submitted That Met QC Criteria: August 24, 2015
• Last Verified: August 1, 2015

More Information

Terms related to this study

• Other Study ID Numbers: KEK-ZH-Nr. 2014-0408